Extravasation of [
Extravasation
Kidney dosimetry
Peptide-receptor radionuclide therapy (PRRT)
[177Lu]Lu-DOTATOC
Journal
EJNMMI research
ISSN: 2191-219X
Titre abrégé: EJNMMI Res
Pays: Germany
ID NLM: 101560946
Informations de publication
Date de publication:
23 Jun 2020
23 Jun 2020
Historique:
received:
15
04
2020
accepted:
09
06
2020
entrez:
25
6
2020
pubmed:
25
6
2020
medline:
25
6
2020
Statut:
epublish
Résumé
In the case of extravasation of radioactive drugs used in peptide-receptor radionuclide therapy of neuroendocrine tumors, or in radionuclide therapy in general, rapid action is important to reduce or avoid complications. The literature on extravasation of drugs for radionuclide therapy is sparse. Based on the present case, we discuss handling and consequences of extravasation. Further, we demonstrate that dosimetry can aid in judging if the treatment of neuroendocrine tumors is satisfactory even after extravasation. A case of extravasation of [ The treatment of extravasation was successful, and the redistribution of the drug can be easily verified through measurement of the dose rate at contact with the skin. From the results of dosimetry, it was assessed that no change of the treatment course was necessary to compensate for a possibly incomplete treatment as a result of the extravasation.
Sections du résumé
BACKGROUND
BACKGROUND
In the case of extravasation of radioactive drugs used in peptide-receptor radionuclide therapy of neuroendocrine tumors, or in radionuclide therapy in general, rapid action is important to reduce or avoid complications. The literature on extravasation of drugs for radionuclide therapy is sparse. Based on the present case, we discuss handling and consequences of extravasation. Further, we demonstrate that dosimetry can aid in judging if the treatment of neuroendocrine tumors is satisfactory even after extravasation.
CASE PRESENTATION
METHODS
A case of extravasation of [
CONCLUSIONS
CONCLUSIONS
The treatment of extravasation was successful, and the redistribution of the drug can be easily verified through measurement of the dose rate at contact with the skin. From the results of dosimetry, it was assessed that no change of the treatment course was necessary to compensate for a possibly incomplete treatment as a result of the extravasation.
Identifiants
pubmed: 32577838
doi: 10.1186/s13550-020-00658-6
pii: 10.1186/s13550-020-00658-6
pmc: PMC7311613
doi:
Types de publication
Journal Article
Langues
eng
Pagination
68Références
Proc (Bayl Univ Med Cent). 2017 Jan;30(1):78-79
pubmed: 28127143
Clin J Oncol Nurs. 2008 Apr;12(2):275-8
pubmed: 18390463
Ann ICRP. 2002;32(3-4):5-265
pubmed: 14506981
Ann ICRP. 2008;38(3):7-96
pubmed: 19285593
Ann Chir Plast Esthet. 2018 Apr;63(2):175-181
pubmed: 29290464
J Nucl Med. 2016 Jan;57(1):151-62
pubmed: 26471692
N Engl J Med. 2017 Jan 12;376(2):125-135
pubmed: 28076709
J Nucl Med. 2011 Sep;52(9):1418-22
pubmed: 21795365
Cancer Biother Radiopharm. 2006 Apr;21(2):101-5
pubmed: 16706630
Eur J Nucl Med Mol Imaging. 2007 Apr;34(4):616-22
pubmed: 17323056
Nucl Med Commun. 2017 May;38(5):357-365
pubmed: 28338529
Eur J Nucl Med Mol Imaging. 2013 May;40(5):800-16
pubmed: 23389427
Eur J Nucl Med Mol Imaging. 2017 Jul;44(7):1234-1243
pubmed: 28303300
Cancer Imaging. 2011 Jun 15;11:56-66
pubmed: 21684829
Clin Nucl Med. 2017 Aug;42(8):639-640
pubmed: 28574879
Eur J Nucl Med Mol Imaging. 2018 May;45(5):824-845
pubmed: 29234845